SVRA Logo

Savara Inc. (SVRA) 

NASDAQ
Market Cap
$556.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
159 of 774
Rank in Industry
97 of 432

Largest Insider Buys in Sector

SVRA Stock Price History Chart

SVRA Stock Performance

About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Insider Activity of Savara Inc.

Over the last 12 months, insiders at Savara Inc. have bought $346,672 and sold $885,323 worth of Savara Inc. stock.

On average, over the past 5 years, insiders at Savara Inc. have bought $3.32M and sold $481,596 worth of stock each year.

Highest buying activity among insiders over the last 12 months: RAMSAY DAVID A (director) — $575,200. McCracken Joseph S (director) — $118,144.

The last purchase of 20,000 shares for transaction amount of $59,072 was made by McCracken Joseph S (director) on 2024‑11‑19.

List of Insider Buy and Sell Transactions, Savara Inc.

2024-11-19Purchasedirector
20,000
0.0117%
$2.95$59,072+6.48%
2024-11-18Purchasedirector
100,000
0.0566%
$2.88$287,600+2.92%
2023-12-28SaleCHIEF EXECUTIVE OFFICER
84,000
0.0609%
$4.71$395,900-7.39%
2023-12-28SaleCHIEF FINANCIAL OFFICER
10,000
0.0072%
$4.71$47,131-7.39%
2023-12-28Saledirector
93,843
0.068%
$4.71$442,291-7.39%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-07-17Purchase10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2023-06-26PurchaseChief Medical Officer
6,500
0.0047%
$2.93$19,045+53.21%
2023-05-26Purchasedirector
37,124
0.024%
$2.63$97,599+44.36%
2023-05-25Purchasedirector
12,876
0.0084%
$2.57$33,130+48.84%
2023-05-24Purchasedirector
50,000
0.0322%
$2.56$127,800+47.69%
2022-12-30Purchasedirector
29,000
0.0189%
$1.55$44,834+101.94%

Insider Historical Profitability

33.32%
RAMSAY DAVID Adirector
2323642
1.354%
$3.25520+40.1%
Pauls MatthewCHIEF EXECUTIVE OFFICER
1302674
0.759%
$3.25101<0.0001%
Lowrance David LCHIEF FINANCIAL OFFICER
342355
0.1995%
$3.25311+23.24%
McCracken Joseph Sdirector
210837
0.1229%
$3.2530+29.35%
SANDELL SCOTT D10 percent owner
24471264
14.2591%
$3.2510

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$121.87M14.8824.47M0%+$00.57
Bain Capital Life Sciences Investors Llc$72.54M8.8614.57M+2.34%+$1.66M5.84
Tcg Crossover Management Llc$49.8M6.0810M0%+$00.08
JENNISON ASSOCIATES LLC$44.03M5.388.84M+0.3%+$132,532.730.03
Adage Capital Partners Gp L L C$41.27M5.048.29M+8.51%+$3.24M0.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.